Reddy Nishitha M, Perales Miguel-Angel
Division of Hematology/Oncology, Vanderbilt University Medical Center, 3927 The Vanderbilt Clinic, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA.
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 298, New York, NY 10065, USA.
Hematol Oncol Clin North Am. 2014 Dec;28(6):1097-112. doi: 10.1016/j.hoc.2014.08.011. Epub 2014 Sep 26.
Patients with Hodgkin lymphoma (HL) who relapse following effective front-line therapy are offered salvage second-line chemotherapy regimens followed by high-dose therapy and autologous stem cell transplantation (HDT/ASCT). Randomized studies comparing HDT/ASCT with conventional chemotherapy in patients with relapsed refractory HL have shown significant improvement in progression-free survival and freedom from treatment failure but were not powered to show improvements in overall survival. For patients who relapse after salvage HDT/ASCT, novel therapies exist as a bridge to allogeneic SCT. In this article, we review indications and results of autologous and allogeneic SCT in HL.
接受有效一线治疗后复发的霍奇金淋巴瘤（HL）患者会接受挽救性二线化疗方案，随后进行大剂量治疗和自体干细胞移植（HDT/ASCT）。比较HDT/ASCT与传统化疗用于复发难治性HL患者的随机研究显示，无进展生存期和无治疗失败生存期有显著改善，但尚无足够的效力显示总生存期有所改善。对于挽救性HDT/ASCT后复发的患者，存在新型疗法作为异基因造血干细胞移植（SCT）的过渡。在本文中，我们综述了HL患者自体和异基因SCT的适应证及结果。
